In-situ multiomics is revolutionizing research in oncology, immunology and neurobiology. However, speed and throughput are major bottlenecks for these critical studies. Here, we present data from a ...

SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower ...

Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?

A cancer diagnosis often comes with overwhelming emotions and a flood of unfamiliar medical terms that can spark even more fear. But understanding these terms can help you feel more in control of your ...

We combine advanced technologies such as spatial transcriptomics, multiplexed imaging, and in situ sequencing to map cellular components in their native tissue context. Obtain high-resolution data ...

Please provide your email address to receive an email when new articles are posted on . A significant number of women with non-screen-detected ductal carcinoma in situ had invasive cancer or breast ...

Like many cancer patients, Michael Wolff wanted answers. But, like many cancer patients in 2015, he wasn't getting them. After years of lymphoma treatment, the renowned jazz musician was still sick ...